Cendifensine

Cendifensine
Clinical data
Other names	NOE-115
Drug class	Monoamine reuptake inhibitor
Identifiers
	IUPAC name (3,4-dichlorophenyl)-[(3S)-3-propylpyrrolidin-3-yl]methanone;
CAS Number	1034048-49-1;
PubChem CID	59744668;
ChemSpider	42806369;
UNII	N4U2JR8GCX;
Chemical and physical data
Formula	C14H17Cl2NO
Molar mass	286.20 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC[C@@]1(CCNC1)C(=O)C2=CC(=C(C=C2)Cl)Cl;
	InChI InChI=1S/C14H17Cl2NO/c1-2-5-14(6-7-17-9-14)13(18)10-3-4-11(15)12(16)8-10/h3-4,8,17H,2,5-7,9H2,1H3/t14-/m0/s1; Key:HVLPRTLORBIKNG-AWEZNQCLSA-N;

Cendifensine (INNTooltip International Nonproprietary Name) is a monoamine reuptake inhibitor (MRI)^[1] related to the amphetamines and cathinones which has not been marketed at this time.^[2]^[3]^[4] It was first described by 2013^[4] and its INNTooltip International Nonproprietary Name was proposed in 2024.^[2] The drug has been patented by Noema Pharma, which is developing a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) known as NOE-115 for the treatment of vasomotor symptoms associated with menopause^[5] as well as for binge-eating disorder and depressive disorders.^[6]^[7]^[8]